Literature DB >> 35077743

Tissue-reactive drugs enable materials-free local depots.

Sharda Pandit1, Sandeep Palvai2, Nicholas P Massaro3, Joshua G Pierce3, Yevgeny Brudno4.   

Abstract

Local, sustained drug delivery of potent therapeutics holds promise for the treatment of a myriad of localized diseases while eliminating systemic side effects. However, introduction of drug delivery depots such as viscous hydrogels or polymer-based implants is highly limited in stiff tissues such as desmoplastic tumors. Here, we present a method to create materials-free intratumoral drug depots through Tissue-Reactive Anchoring Pharmaceuticals (TRAPs). TRAPs diffuse into tissue and attach locally for sustained drug release. In TRAPs, potent drugs are modified with ECM-reactive groups and then locally injected to quickly react with accessible amines within the ECM, creating local drug depots. We demonstrate that locally injected TRAPs create dispersed, stable intratumoral depots deep within mouse and human pancreatic tumor tissues. TRAPs depots based on ECM-reactive paclitaxel (TRAP paclitaxel) had better solubility than free paclitaxel and enabled sustained in vitro and in vivo drug release. TRAP paclitaxel induced higher tumoral apoptosis and sustained better antitumor efficacy than the free drug. By providing continuous drug access to tumor cells, this material-free approach to sustained drug delivery of potent therapeutics has the potential in a wide variety of diseases where current injectable depots fall short.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Extracellular matrix; Materials-free delivery; N-hydroxysuccinimide ester; Paclitaxel; Pancreatic cancer; Sustained release

Mesh:

Substances:

Year:  2022        PMID: 35077743      PMCID: PMC8960365          DOI: 10.1016/j.jconrel.2022.01.023

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  54 in total

1.  EUS-guided injection of paclitaxel (OncoGel) provides therapeutic drug concentrations in the porcine pancreas (with video).

Authors:  Kai Matthes; Mari Mino-Kenudson; Dushyant V Sahani; Nagaraj Holalkere; Kirk D Fowers; Ramesh Rathi; William R Brugge
Journal:  Gastrointest Endosc       Date:  2006-12-14       Impact factor: 9.427

Review 2.  Combinatorial drug delivery approaches for immunomodulation.

Authors:  Joshua M Stewart; Benjamin G Keselowsky
Journal:  Adv Drug Deliv Rev       Date:  2017-05-19       Impact factor: 15.470

3.  Synthesis of a Fluorescent Analogue of Paclitaxel That Selectively Binds Microtubules and Sensitively Detects Efflux by P-Glycoprotein.

Authors:  Molly M Lee; Zhe Gao; Blake R Peterson
Journal:  Angew Chem Int Ed Engl       Date:  2017-05-09       Impact factor: 15.336

Review 4.  Pharmaceutical implants: classification, limitations and therapeutic applications.

Authors:  Zahra Mohtashami; Zahra Esmaili; Molood Alsadat Vakilinezhad; Ehsan Seyedjafari; Hamid Akbari Javar
Journal:  Pharm Dev Technol       Date:  2019-11-12       Impact factor: 3.133

Review 5.  Ablative Therapies for Locally Advanced Pancreatic Cancer.

Authors:  Rupen Shah; Katherine T Ostapoff; Boris Kuvshinoff; Steven N Hochwald
Journal:  Pancreas       Date:  2018-01       Impact factor: 3.327

6.  Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors.

Authors:  Alastair H Kyle; Lynsey A Huxham; Devon M Yeoman; Andrew I Minchinton
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

7.  Molecular mechanism of local drug delivery with Paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug.

Authors:  Sookhee Bang; Sung Ill Jang; Su Yeon Lee; Yi-Yong Baek; Jieun Yun; Soo Jin Oh; Chang Woo Lee; Eun Ae Jo; Kun Na; Sugeun Yang; Don Haeng Lee; Dong Ki Lee
Journal:  Gastroenterol Res Pract       Date:  2015-04-23       Impact factor: 2.260

Review 8.  Current Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines.

Authors:  Mikhail O Durymanov; Andrey A Rosenkranz; Alexander S Sobolev
Journal:  Theranostics       Date:  2015-06-08       Impact factor: 11.556

9.  Programmed Hydrolysis in Designing Paclitaxel Prodrug for Nanocarrier Assembly.

Authors:  Q Fu; Y Wang; Y Ma; D Zhang; J K Fallon; X Yang; D Liu; Z He; F Liu
Journal:  Sci Rep       Date:  2015-07-13       Impact factor: 4.379

Review 10.  Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions.

Authors:  Maximilian Brunner; Zhiyuan Wu; Christian Krautz; Christian Pilarsky; Robert Grützmann; Georg F Weber
Journal:  Int J Mol Sci       Date:  2019-09-13       Impact factor: 5.923

View more
  1 in total

Review 1.  Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies.

Authors:  Alaa Y Bazeed; Candace M Day; Sanjay Garg
Journal:  Cancers (Basel)       Date:  2022-08-31       Impact factor: 6.575

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.